GlassScriptPhysician profile
William Caceres
NPI 1518910801
$1,311.84
in general payments reported to CMS, 2019-2025
24 companies · $613 in 2025
The $613 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $28.03 · 2021: $70.79 · 2022: $20.00 · 2023: $136 · 2024: $253 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $181.20 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $166.19 | 2019-2025 | Keytruda, Keytruda Qlex |
| Pbg Puerto Rico LLC | $144.16 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $136.16 | 2023 | Empaveli |
| Eisai INC. | $119.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $63.40 | 2025 | Opdivo, Opdualag |
| Celgene Corporation | $57.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $54.52 | 2019-2025 | Enhertu |
| Taiho Oncology, INC. | $42.63 | 2021-2024 | |
| Amgen INC. | $42.00 | 2025 | Imdelltra (Amg757), Lumakras, Xgeva |
| Janssen Pharmaceuticals, INC | $38.19 | 2025 | Rybrevant |
| Lantheus Medical Imaging, INC. | $28.03 | 2020 | |
| Genentech USA, INC. | $26.96 | 2025 | Phesgo |
| Jazz Pharmaceuticals INC. | $22.95 | 2025 | |
| Telix Pharmaceuticals | $22.95 | 2025 | Illuccix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $22.55 | 2025 | |
| Genmab U.S., INC. | $22.47 | 2024 | Epkinly |
| Caris Mpi, INC. | $21.42 | 2025 | Mi Cancer Seek |
| Eli Lilly Export S.A. Puerto Rico Branch | $21.28 | 2025 | Verzenio, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $20.66 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $19.62 | 2019 | |
| Pfizer INC. | $19.33 | 2024 | |
| Clovis Oncology, INC. | $17.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Caceres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.